Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

The network

Rosalind Study

Inside Cure51

Event

Publication Date:

It was a pleasure to take part in the Servier x Paris-Saclay Cancer Cluster Annual Event, a key gathering focused on advancing innovation in oncology through public-private partnerships.

Our CEO, Nicolas Wolikow, joined a roundtable at the Servier R&D Institute in Paris-Saclay. The event, co-organized by Servier and the Paris-Saclay Cancer Cluster, brought together key players from the oncology ecosystem. During the roundtable, he shared insights on how biotech startups and pharmaceutical companies can strengthen partnerships to accelerate drug development and bring innovative Cancer therapies to patients faster.

Nicolas Wolikow joined a panel of leading experts, including Julien Elric (Jeito Life Sciences), Emmanuel Gomez (Inatherys), Simon Pico (Hephaistos Pharma), François Lehembre (Servier) and Lucie Mondoulet (PSCC Boost). The session was moderated by Alix Scholher-Dahirel.

This event underscores the importance of collaboration between startups and pharma, fostering a strong ecosystem for oncology innovation in Europe.

cure51-servier-paris-saclay-pscc-annual-event


Updated: April 7, 2026

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.